Altered expression and activation of signal transducers and activators of transcription (STATs) in hepatitis C virus infection: In vivo and in vitro studies

Gut

Volumn 55, Issue 8, 2006, Pages 1188-1196

  Larrea, E ^b   Aldabe, R ^b   Molano, E ^b   Fernandez Rodriguez, C M ^c   Ametzazurra, A ^b   Civeira, M P ^b   Prieto, J ^a,b  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

^c HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ALPHA INTERFERON RECEPTOR; CARDIOTROPHIN 1; CYTOKINE; GAMMA INTERFERON; JANUS KINASE; STAT1 PROTEIN; STAT2 PROTEIN; STAT3 PROTEIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMOGRAPHY; GENE MUTATION; GENETIC REGULATION; GENETIC TRANSFECTION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKOCYTE; LIVER CELL; PARENCHYMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REPLICON; STAINING; VIRUS REPLICATION;

CELL LINE; DOWN-REGULATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; POLYMERASE CHAIN REACTION; RECEPTORS, INTERFERON; REPLICON; RNA, MESSENGER; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS; STAT1 TRANSCRIPTION FACTOR; STAT2 TRANSCRIPTION FACTOR; STAT3 TRANSCRIPTION FACTOR; VIRAL LOAD; VIRUS REPLICATION;

EID: 33746139034     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2005.070060     Document Type: Article

References (38)

1. Ihle JN. The Stat family in cytokine signaling. Curr Opin Cell Biol 2001;13:211-17.
2. David M. Signal transduction by type I interferons. Biotechniques 2002;(Suppl):58-65.
3. Heim MH. Intracellular signalling and antiviral effects of interferons. Dig Liver Dis 2000;32:257-63.
4. A Yang CH, Murti A, Pfeffer LM. STAT3 complements defects in an interferon-resistant cell line: evidence for an essential role for STAT3 in interferon signaling and biological activities. Proc Natl Acad Sci U S A 1998;95:5568-72.
5. Zhu H, Shang X, Terada N, et al. STAT3 induces anti-hepatitis C viral activity in liver cells. Siochem Biophys Res Commun 2004;324:518-28.
6. Haga S, Terui K, Zhang HQ, et al. Stat3 protects against Fas-induced liver injury by redox-dependent and -independent mechanisms. J Clin Invest 2003;112:989-98.
7. Jacoby JJ, Kalinowski A, Liu MG, et al. Cardiomyocyte-restricted knockout of STAT3 results in higher sensitivity to inflammation, cardiac fibrosis, and heart failure with advanced age. Proc Natl Acad Sci U S A 2003;100:12929-34.
8. Williams L, Bradley L, Smith A, et al. Signal transducer and activator of transcription 3 is the dominant mediator of the anti-inflammatory effects of IL-10 in human macrophages. J Immunol 2004;172:567-76.
9. Bustos M, Beraza N, Lasarte JJ, et al. Protection against liver damage by cardiotrophin-1: a hepatocyte survival factor up-regulated in the regenerating liver in rats. Gastroenterology 2003;125:192-201.
10. Beraza N, Marques JM, Martinez-Anso E, et al. Interplay among cardiotrophin-1, prostaglandins, and vascular endothelial growth factor in rat liver regeneration. Hepatology 2005;41:460-9.
11. Klein C, Wustefeld T, Assmus U, et al. The IL-6-gp130-STAT3 pathway in hepatocytes triggers liver protection in T cell-mediated liver injury. J Clin Invest 2005;115:860-9.
12. Kovalovich K, DeAngelis RA, Li W, et al. Increased toxin-induced liver injury and fibrosis in interleukin-6-deficient mice. Hepatology 2000;31:149-59.
13. Taub R. Hepatoprotection via the IL-6/Stat3 pathway. J Clin Invest 2003;112:978-80.
14. Ernst M, Jenkins BJ. Acquiring signalling specificity from the cytokine receptor gp130. Trends Genet 2004;20:23-32.
15. Heinrich PC, Behrmann I, Muller-Newen G, et al. Interleukin-6-type cytokine signalling through the gp1430/Jak/STAT pathway. Biochem J 1998;334:297-314.
16. Pestka S. The human interferon alpha species and receptors. Biopolymers 2000;55:254-87.
17. Pfeffer LM, Basu L, Pfeffer SR, et al. The short form of the interferon alpha/beta receptor chain 2 acts as a dominant negative for type I interferon action. J Biol Chem 1997;272:11002-5.
18. Lau JF, Horvath CM. Mechanisms of type I interferon cell signaling and STAT-mediated transcriptional responses. Mt Sinai J Med 2002;69:156-68.
19. Stark GR, Kerr IM, Williams BR, et al. How cells respond to interferons. Annu Rev Biochem 1998;67:227-64.
20. Krebs DL, Hilton DJ. SOCS: physiological suppressors of cytokine signaling. J Cell Sci 2000;113:2813-19.
21. Song MM, Shuai K. The suppressor of cytokine signaling (SOCS) 1 and SOCS3 but not SOCS2 proteins inhibit interteron-mediated antiviral and antiproliferative activities. J Biol Chem 1998;273:35056-62.
22. Chung CD, Liao J, Liu B, et al. Specific inhibition of Stat3 signal transduction by PIAS3. Science 1997;278:1803-5.
23. Liao J, Fu Y, Shuai K. Distinct roles of lhe NH2- and COOH-terminal domains of the protein inhibitor of activated signal transducer and activator of transcription (STAT) 1 (PIAS1) in cytokine-induced PIAS1-Stat1 interaction. Proc Natl Acad Sci U S A 2000;97:5267-72.
24. Pietschmann T, Lohmann V, Kaul A, et al. Persistent and transient replication of full-length hepatitis C virus genomes in cell culture. J Virol 2002;76:4008-21.
25. Chomcynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biocnem 1987;162:156-9.
26. Caldenhoven E, van Dijk TB, Solari R, et al. STAT3beta, a splice variant of transcription factor STAT3, is a dominant negative regulator of transcription. J Biol Chem 1996;271:13221-7.
27. Meydan N, Grunberger T, Dadi H, et al. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature 1996;379:645-8.
28. Gotoh B, Takeuchi K, Komatsu T, et al. The STAT2 activation process is a crucial target of Sendai virus C protein for the blockade of alpha interferon signaling. J Virol 2003;77:3360-70.
29. Shiffman ML, Di Bisceglie AM, Lindsay KL, et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004;126:1015-23.
30. Heim MH, Moradpour D, Blum HE. Expression of hepatitis C virus proteins inhibits signal transduction through the Jak-STAT pathway. J Virol 1999;73:8469-75.
31. Blindenbacher A, Duong FH, Hunziker L, et al. Expression of hepatitis C virus proteins inhibits interferon alpha signaling in the liver of transgenic mice. Gastroenterology 2003;124:1465-75.
32. Basu A, Meyer K, Ray RB, et al. Hepatitis C virus core protein modulates the interferon-induced transacting factors of Jak/Stat signaling pathway but does not affect the activation of downstream IRF-1 or 561 gene. Virology 2001;288:379-90.
33. Duong FH, Filipowicz M, Tripodi M, et al. Hepatitis C virus inhibits interferon signaling through up-regulation of protein phosphatase 2A. Gastroenterology 2004;126:263-77.
34. Lin W, Choe WH, Hiasa Y, et al. Hepatitis C virus expression suppresses interferon signaling by degrading STAT1. Gastroenterology 2005;128:1034-41.
35. Napoli J, Bishop GA, McGuinness PH, et al. Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1-associated cytokines. Hepatology 1996;24:759-65.
36. Bach EA, Aguet M, Schreiber RD. The IFN gamma receptor: a paradigm for cytokine receptor signaling. Annu Rev Immunol 1997;15:563-91.
37. Morita K, Tanaka K, Saito S, et al. Expression of interferon receptor genes in the liver as a predictor of interferon response in patients with chronic hepatitis C. J Med Virol 1999;58:359-65.
38. Yatsuhashi H, Fujino T, Matsumoto T, et al. Immunohistochemical analysis of hepatic interferon alpha-beta receptor level: relationship between receptor expression and response to interferon therapy in patients with chronic hepatitis C. J Hepatol 1999;30:995-1003.